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a b s t r a c t
Objective: To develop and internally validate a prognostic model for perinatal death that could guide
community-based antenatal care of women with a hypertensive disorder of pregnancy (HDP) in low-
resourced settings as part of a mobile health application.
Study design: Using data from 1688 women (110 (6.5%) perinatal deaths) admitted to hospital after
32 weeks gestation with a HDP from five low-resourced countries in the miniPIERS prospective cohort,
a logistic regression model to predict perinatal death was developed and internally validated. Model dis-
crimination, calibration, and classification accuracy were assessed and compared with use of gestational
age alone to determine prognosis.
Main outcome measures: Stillbirth or neonatal death before hospital discharge.
Results: The final model included maternal age; a count of symptoms (0, 1 orP2); and dipstick protein-
uria. The area under the receiver operating characteristic curve was 0.75 [95% CI 0.71–0.80]. The model
correctly identified 42/110 (38.2%) additional cases as high-risk (probability >15%) of perinatal death
compared with use of only gestational age <34 weeks at assessment with increased sensitivity (48.6%
vs. 23.8%) and similar specificity (86.6% vs. 90.0%).
Conclusion: Using simple, routinely collected measures during antenatal care, we can identify women
with a HDP who are at increased risk of perinatal death and who would benefit from transfer to
facility-based care. This model requires external validation and assessment in an implementation study
to confirm performance.
 2015 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V.
1. Introduction
Perinatal death, including stillbirth and neonatal death up to
28 days of life, remains a significant health burden, globally. By
most recent estimates, there were an estimated 2.64 million still-
births in 2009, 76.2% of which were in Sub-Saharan Africa or South
Asia [1,2]. Global neonatal and child death rates show a similar
trend, with an estimated 2.00 million early neonatal deaths in
2013 and 80% of all child deaths reported in just 26 low- and
middle-income countries [3]. The hypertensive disorders of preg-
nancy are responsible for an estimated 9–20% of all perinatal
deaths [2,11–14].
Like maternal death, perinatal death is increased in low- and
middle-income countries compared with high-income countries
due to a lack of access to effective antenatal and emergency obstet-
ric care, as well as demographic and social risk factors which
include advanced and very young maternal age, being unmarried,
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low socioeconomic status, illiteracy, and undernutrition [5–7]. As
such, the majority of these deaths are preventable [4–6], by
improving both the access to, and quality of, maternal antenatal
care [8–10]. For women with the hypertensive disorders of preg-
nancy, this improvement in care would include improved diagno-
sis in the community and timely referral to a higher-level facility,
should a woman be identified to be at risk of a serious
complication.
We have previously developed and validated the miniPIERS
(Pre-eclampsia Integrated Estimate of RiSk) model that can identify
which women with a hypertensive disorder of pregnancy are at
greatest risk of poor maternal outcome [15]. This model has been
converted into a mobile health (mHealth) application, called PIERS
on the Move [16], for use by frontline health workers as a decision
aid for diagnosis and timely triage of women with hypertension
identified in the community. In order to broaden the impact of
the PIERS on the Move tool and facilitate improvements in perina-
tal outcomes, a complimentary model for community-level identi-
fication of hypertensive pregnant women who are at greatest risk
of perinatal death is required.
Using data from the miniPIERS cohort, the objective of this
study was to determine if the maternal demographics and clinical
symptoms and signs measured during antenatal surveillance could
be used to identify the fetuses at greatest risk of perinatal death.
2. Materials and methods
2.1. Study design and population
The miniPIERS cohort is a prospective, multicentre cohort of
women with a hypertensive disorder of pregnancy collected from
July 2008 to March 2012. A detailed description of the cohort has
been previously published [15]. The study was approved by the
University of British Columbia clinical research ethics board and
each participating institutions clinical research ethics board. All
participating women provided written informed consent for inclu-
sion into the miniPIERS cohort.
Women were included in miniPIERS if they were admitted to a
participating institution with any of the hypertensive disorders of
pregnancy: chronic hypertension, gestational hypertension, pre-
eclampsia, or isolated HELLP (Hemolysis Elevated Liver enzyme
Low Platelet) syndrome. Women were excluded if: (i) they had suf-
fered a primary maternal outcome for the main study prior to
admission to hospital, or (ii) they had been admitted to hospital
with either a CD4 count <250 or an AIDS-defining illness, as these
were felt to be significant confounders of the disease-maternal out-
come relationship. These inclusion and exclusion criteria have
been previously described [15].
For this study, the cohort was further restricted to include only
singleton pregnancies and cases with admission after 32 weeks
gestation, to optimize the clinical relevance of the model. First,
perinatal risk in the very early preterm period before 32 weeks
gestation would be driven almost entirely by gestational age. Sec-
ond, in under-resourced settings, neonatal survival is unlikely
when delivery occurs prior to 32 weeks, but thereafter, survival
is likely in any setting with basic newborn care [17]. Having a
model that identifies those women likely to benefit from facility-
based care for their high-risk neonates after 32 weeks gestation
is therefore needed.
2.2. Candidate predictor variables
For this study, candidate predictor variables were defined prior
to analysis as: (i) those demonstrated to increase risk of stillbirth
or neonatal death in previous studies [19,20] as well as (ii) those
related to the severity of the maternal condition in the miniPIERS
model [15,18]. Specifically, we assessed gestational age on admis-
sion (weeks), parity (primiparous or multiparous), maternal age
(years), smoking status (non-smoker/smoker), blood pressure
(mmHg), dipstick proteinuria, and the maternal symptoms of
headache, visual disturbances, chest pain, dyspnoea, right upper
quadrant pain or epigastric pain, nausea/vomiting, and vaginal
bleeding with abdominal pain.
The value of the candidate predictor used in the model develop-
ment process was the worst measured within the first 24 h of
admission. There was no missing data for candidate predictors
within this timeframe in the miniPIERS cohort. As this was a sec-
ondary analysis of the existing cohort, during ascertainment of
the predictor variables data collectors were unaware of the out-
come status of the baby.
2.3. Perinatal outcome
A composite of stillbirth or neonatal death was used to define
the primary outcome. The study cohort was restricted to those
women admitted after 32 weeks gestation, so only cases of still-
birth occurring after admission at this time point are considered.
Neonatal death was limited to that occurring during hospital
admission, as follow-up post-discharge for women or their babies
was not possible.
2.4. Sample size
The sample size required for model development was deter-
mined based on the minimum standard of 10 events per effective
variable considered, according to the formula N = (n  10)/I where
N is the sample size, n is the number of candidate predictor vari-
ables and I is the estimated event rate in the population [21]. As
this was a secondary analysis of an existing cohort of known size,
this formula was used to determine the number of candidate pre-
dictor variables that could reasonably be tested in a multivariable
model. Based on a perinatal death rate of 6.5% in the miniPIERS
cohort and the cohort size of 1688 women, we determined that a
maximum of 10 candidate predictor variables should be
considered.
2.5. Statistical analysis
2.5.1. Descriptive analysis of the cohort
Women with and without perinatal death were compared using
the Mann–Whitney U test for continuous variables and the chi-
squared or Fischer’s exact test for categorical variables.
2.5.2. Selection of candidate predictor variables
Associations with perinatal death were estimated using logistic
regression to determine univariate and gestational age-adjusted
odds ratios for all candidate predictor variables. Also, associations
between candidate predictor variables were estimated by using
either the Pearson product moment correlation coefficient or
two-by-two tables and the chi-squared statistic, where appropri-
ate; this was done in order to reduce possible correlation between
predictor variables included in the model. Final predictor variables
to be included in the multivariable model were selected based on
the strength of the gestational age-adjusted association with peri-
natal death, as well as the lack of evidence of correlation with other
predictors. A final selection rule based on a minimum change in
area under the receiver operating characteristic curve (AUC ROC)
of 0.2 after inclusion of the candidate predictor variable being con-
sidered was implemented to ensure that the final model was as
parsimonious as possible, given the environment in which it is
meant to be used.
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2.5.3. Final model development and evaluation
Multivariable logistic regression was used to estimate the
strength of association between the final predictors included in
the model with perinatal death, the primary outcome. This final
model was evaluated based on discrimination ability using the area
under the receiver-operating-characteristic curve (AUC ROC). An
AUC ROC P0.70 is considered as evidence of good discrimination
[22].
Calibration of the final multivariable model was assessed based
on the Hosmer–Lemeshow goodness-of-fit test and, visually, by
plotting predicted probability of perinatal death against the
observed rate of the outcome in each decile. Stratification capacity
of the model was tabulated in five groups of predicted probability
as the number of events in each group out of the total cases in that
group. Groups were defined so that the lowest and highest groups
included only those women with significantly lower or higher pre-
dicted probabilities than the population prevalence of perinatal
death (6.5%). Predictive performance, defining high-risk cases
based on the threshold of predictive probability used to define each
of the five risk groups, was estimated using the sensitivity, speci-
ficity, positive predictive value and negative predictive value.
Finally, a likelihood ratio was estimated for each risk group individ-
ually [23].
2.5.4. Model validation
Internal validity of the final multivariable model was assessed
using Efron’s enhanced bootstrap method [24]. Also, evaluation
of the final model for classification accuracy was based on a com-
parison with both the published miniPIERS model and gestational
age alone. To accomplish this, a classification table was used in
which women were classified as high-risk based on a miniPIERS
maternal model predicted probability P25% or a gestational age
at admission <34 weeks; these results were compared with the
perinatal model using a risk-threshold of >15% predicted probabil-
ity of perinatal death. Gestational age alone was chosen as a com-
parator to reflect the standard of practice in the study settings; it is
the most commonly used indicator for risk of stillbirth and neona-
tal death in this population.
Sensitivity analyses were performed to assess the performance
of the model based on its discrimination ability when the outcome
was restricted to either stillbirth or neonatal death before dis-
charge. Further sensitivity analyses assessed the performance of
the model when the cohort was restricted to those women admit-
ted after 34 weeks gestation or after 36 weeks gestation.
All statistical analyses were performed using STATA version
13.1 (STATA Corp, Texas, USA).
3. Results
Of the 2081 women in the miniPIERS cohort, 1688 (81.1%) were
included in this study after exclusion of 78 cases with multiple ges-
tation and 323 cases admitted prior to 32 weeks gestation. Among
these 1688 women, there were 110 (6.5%) perinatal deaths, of
Table 1
Demographics of women in the total cohort comparing women with and without perinatal death (N = 1688). Results for continuous variables presented as mean (±sd) when data
normally distributed or median [interquartile range] for skewed data.
Characteristic Women with adverse neonatal
outcomes (n = 110 women)
Women without adverse neonatal
outcomes (n = 1578 women)
p*
Demographics (within 48 h of eligibility)
Maternal age at EDD (year) 28 [25, 32] 28 [24, 32] 0.336
Age > 40 years 7 (6.3%) 73 (4.6%) 0.407
Gestational age at admission (week) 36.6 [34.1, 38.6] 37.6 [35.9, 39.1] <0.001
ParityP 1 61 (55.5%) 824 (52.2%) 0.554
Smoking in this pregnancy 1 (0.9%) 47 (3.0%) 0.366
Hypertensive disorder description
Pre-eclampsia 91 (82.7%) 911 (57.7%) <0.001
miniPIERS maternal predicted probability (%) 12.2 [7.6, 22.3] 7.2 [5.2, 11.7] <0.001
Clinical measures (within 24 h of eligibility)
Systolic BP 160 [150, 180] 150 [140, 170] <0.001
Diastolic BP 110 [100, 120] 100 [90, 110] <0.001
Worst dipstick proteinuria 2+ [2+, 3+] 1+ [negative, 3+] <0.001
Maternal symptoms
Headache 77 (70.0%) 640 (40.6%) <0.001
Visual disturbances 52 (47.3%) 335 (21.2%) <0.001
Chest pain 7 (6.4%) 35 (2.2%) 0.017
Dyspnoea 11 (10.0%) 60 (3.8%) 0.005
Epigastric/right upper quadrant pain 47 (42.7%) 222 (14.1%) <0.001
Abdominal pain with vaginal bleeding 20 (18.2%) 113 (7.2%) <0.001
Nausea/vomiting 43 (39.1%) 215 (13.6%) <0.001
Interventions at any time
Corticosteroid administration 41 (37.3%) 348 (22.1%) 0.001
Antihypertensive medications administered 105 (95.5%) 1457 (92.3%) 0.345
MgSO4 administered 66 (60.0%) 638 (40.4%) <0.001
Maternal indication for delivery 91 (82.7%) 1224 (77.6%) 0.204
Cesarean delivery 42 (38.2%) 1034 (65.5%) <0.001
Pregnancy outcomes
Admission-to-delivery interval (all cases) (d) 1 [1, 3] 1 [1, 4] 0.102
Delivery-to-discharge or death interval (d)Ŧ 2 [2, 4] 3 [2, 4] 0.098
Gestational age on delivery (week) 36.8 [34.3, 39.3] 38.0 [36.6, 39.3] <0.001
Birth weight (g) 1801.3 (±771.7) 2758.7 (±653.7) <0.001
Birth weight <3rd percentile (N babies) 51 (46.4%) 254 (16.1%) <0.001
Maternal adverse outcome 37 (33.6%) 234 (14.8%) <0.001
BP = blood pressure; EDD = estimated date of delivery; HDP = hypertensive disorder of pregnancy; MgSO4 = magnesium sulfate.
* p values calculated using chi-squared test for categorical variables or Mann–Whitney U for continuous variables, as appropriate.
Ŧ Excluding stillbirth cases.
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which 79 were stillbirths and 31 were neonatal deaths prior to
hospital discharge. Only 6.9% of those neonates who survived
remained in hospital for follow-up to 7 days postpartum.
Women who had a perinatal death, compared with those who
did not, showed more severe maternal disease indicators, such as
earlier gestational age at admission, higher median blood pressure
and dipstick proteinuria values, greater occurrence of symptoms
and higher incidence of adverse maternal outcomes (Table 1).
However, there was no difference between the groups in the rate
of delivery due to maternal indication. Women who had a perinatal
loss were less likely to be delivered by cesarean, an association that
was more pronounced when the outcome was restricted to still-
birth alone (OR 0.32 [95% CI 0.22–0.48] vs. OR 0.21 [95% CI 0.13–
0.36], respectively).
The univariate risk factors for perinatal death in this cohort
were gestational age at admission, blood pressure (both systolic
and diastolic), dipstick proteinuria and all maternal symptoms. In
order to make interpretation of the impact of systolic blood pres-
sure more clinically meaningful, the univariate and multivariate
odds ratio reported for this variable reflect a 10 mmHg change in
blood pressure value (Table 2).
3.1. Selection of candidate predictors for model development
Systolic and diastolic blood pressures were highly correlated.
Based on the strong association found in previous studies between
systolic blood pressure and stroke risk [25], and the fact that it can
be measured without a manometer, it was decided to retain sys-
tolic blood pressure for consideration in the final model.
All symptom variables were associated with each other
(p < 0.001 for the chi-squared test). To avoid potential errors in
estimation due to multicollinearity, a count of symptoms present
categorized as zero, one, or greater than or equal to two was
retained for the final model.
Maternal age was retained for the final model despite its lack of
significance in the univariable analysis, as maternal age is a well-
established risk factor for perinatal death within this population
[14].
When the requirement that AUC ROC increase by P0.02 in
order for a variable to be included in the final model, symptoms,
dipstick and maternal age were selected as the most significant
contributors to model performance. Addition of blood pressure to
the model did not have any effect on AUC ROC compared to a
model without blood pressure (AUC ROC 0.753 vs. 0.753) and addi-
tion of gestational age at admission had only minimal effect on the
AUC ROC (AUC ROC 0.753 vs. 0.761).
3.2. Final multivariate model
The equation for the final perinatal death model was: logit (log-
arithm of the odds) (pi) = 4.75 + 0.024 (maternal age) + 0.389
(indicator for presence of one symptom) + 1.338 (indicator for
presence of two or more symptoms) + 1.119 (indicator for dipstick
proteinuria of 2+ or 3+) + 1.457 (indicator for dipstick proteinuria
of 4+).
3.3. Performance of the model
Discrimination ability of the model was good with an AUC ROC
of 0.75 [95% CI 0.71–0.80] (Fig. 1). Among these women who were
admitted at 32 weeks or beyond, gestational age alone as a predic-
tor of perinatal death was associated with an AUC ROC of 0.60 [95%
CI 0.54–0.66]. When the miniPIERS maternal model was used to
predict perinatal death in this study, the AUC ROC was 0.70 [95%
CI 0.65–0.75].
This model was well-calibrated with a Hosmer–Lemeshow
goodness of fit test statistic of 2.14 (p = 0.98). The calibration of
the model is further demonstrated by the model calibration curve,
where the 95% confidence interval around the observed rate of out-
come in each decile group of predicted probability crosses the per-
fect fit line (Fig. 2).
Stratification of the cohort based on the model is moderate,
with the majority of women (54.9%) estimated to have a probabil-
ity of perinatal death less than 5% and 25% of whom have a pre-
dicted probability <2%, which is significantly less than the overall
Table 2
Univariate and adjusted analysis of predictors for perinatal death.
Candidate predictor Univariate or [95% CI] Adjusted for gestational age at admission or [95% CI]
Age at EDD (years) 1.01 [0.98–1.05] 1.01 [0.98–1.04]
Gestational age at admission (weeks) 0.85 [0.79–0.92] n/a
ParityP 1 1.14 [0.77–1.68] 1.09 [0.74–1.62]
Smoking (y/n) 0.30 [0.04–2.19] 0.27 [0.04–1.95]
Systolic BP (10 mmHg) 1.16 [1.08–1.24] 1.13 [1.05–1.22]
Diastolic BP (10 mmHg) 1.34 [1.21–1.49] 1.33 [1.19–1.48]
Proteinuria
Negative/trace/1+ Reference Reference
2+/3+ 4.48 [2.71–7.40] 4.13 [2.49–6.85]
4+ 6.71 [3.62–12.5] 6.24 [3.35–11.61]
Pre-eclampsia (y/n) 3.51 [2.12–5.81] 3.12 [1.87–5.20]
Symptoms (y/n)
Headache 3.42 [2.25–5.20] 3.36 [2.20–5.12]
Visual disturbances 3.33 [2.24–4.93] 3.29 [2.21–4.89]
Chest pain 3.00 [1.30–6.91] 2.76 [1.18–6.44]
Dyspnoea 2.81 [1.43–5.52] 2.95 [1.49–5.84]
RUQ pain 4.56 [3.04–6.82] 4.23 [2.82–6.36]
Nausea/vomiting 4.07 [2.70–6.13] 4.06 [2.69–6.13]
Abdominal pain 2.88 [1.71–4.85] 3.03 [1.79–5.13]
Number of symptoms
0 Reference Reference
1 1.99 [1.12–3.55] 1.97 [1.10–3.52]
P2 6.44 [3.98–10.42] 6.28 [3.87–10.19]
BP = blood pressure; EDD = estimated date of delivery; OR = odds ratio; RUQ = right upper quadrant.
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prevalence within the cohort. Sixteen percent of the women were
assigned a predicted probability in the highest risk group (Table 3).
Table 3 shows the sensitivity, specificity, positive and negative
predictive values differed based on the threshold used to define a
positive test (i.e. women at high-risk of a perinatal loss). As the
threshold used to define high-risk increases, the sensitivity
decreases but the likelihood ratio increases. In no risk group does
the likelihood ratio result in values that would indicate that the
test could be used to clearly rule-in or rule-out the risk of perinatal
death. Using gestational age at delivery less than 34 weeks to
define a high-risk subgroup in this cohort was associated with a
sensitivity of 23.6%, specificity 90.0%, positive predictive value
14.1% and negative predictive value 94.4%.
3.4. Model validation
After 500 iterations of bootstrapping, model optimism was esti-
mated as 0.01 indicating minimal overfitting of the model to the
data.
The final perinatal death model correctly identifies significantly
more high-risk women compared with either gestational age only
(42/110, 38.2% additional women, Table 4a) or the miniPIERS
maternal model (35/110, 31.8% additional women, Table 4b). This
improvement in classification of true positive cases occurred with
a small increase in the false-positive rate compared with using ges-
tational age alone (213/1578, 13.5% vs. 159/1578, 10.1%, respec-
tively) or the miniPIERS maternal model (213/1578, 13.5% vs.
101/1578, 6.4%, respectively).
The sensitivity analysis to assess performance of the model
using stillbirth or neonatal death before discharge as the primary
outcome, or when restricting the cohort to greater than 34 weeks
or 36 weeks gestation on admission, demonstrated that the mod-
el’s discrimination ability was well maintained (Table 5).
4. Discussion
In this study we have developed and internally validated a
novel perinatal risk model using simple measures available at
antenatal assessment. Previous work to predict risk of stillbirth
or perinatal death has been restricted to high-resource neonatal
Fig. 1. Receiver operating characteristic curve for the final miniPIERS perinatal
death model including maternal age (years), dipstick proteinuria (negative/trace/1+
vs. 2+/3+ or 4+) and a count of symptoms present (0 vs. 1 or P2).
Fig. 2. Calibration plot of the miniPIERS neonatal outcome model red line
represents line of perfect fit between observed and predicted outcomes. (For
interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)
Table 3
Risk stratification table to assess the performance of the model for predicting perinatal outcome at varying cut-off values to define a positive test.
Predicted probability (%) # event/# in range (%) Sens (%) Spec (%) PPV (%) NPV (%) LR [95% CI]
0.0–1.9 7/415 (1.7%) n/a n/a n/a n/a 0.24 [0.11–0.53]
2.0–5.0 15/511 (2.9%) 93.6 29.2 8.4 98.5 0.43 [0.26–0.69]
5.1–8.0 24/372 (6.5%) 79.8 57.3 11.5 97.6 0.99 [0.68–1.43]
8.1–15 10/123 (8.1%) 57.8 79.4 16.2 96.5 1.26 [0.68–2.35]
>15.0 54/267 (20.2%) 48.6 86.6 20.0 96.1 3.64 [2.90–4.57]
LR = positive likelihood ratio (calculated using the method of Deeks et al.); NPV = negative predictive value; PPV = positive predictive value; Sens = sensitivity;
Spec = specificity.
Table 4
Classification table to compare classification accuracy of the final model (using a
predicted probability of >15.0% to define high-risk) vs. (a) gestational age alone (using
a gestational age of 32–34 weeks at delivery to define high-risk) or (b) the published
miniPIERS model (using predicted probability P25% to define high-risk).
(a) GA alone Final multivariate model Total
Low-risk High-risk
Women with events
Low-risk 42 42 84
High-risk 14 12 26
Total 56 54 110
Women without events
Low-risk 1230 189 1419
High-risk 135 24 159
Total 1365 213 1578
(b) miniPIERS maternal model Final multivariate model Total
Low-risk High-risk
Women with events
Low-risk 54 35 89
High-risk 2 19 21
Total 73 47 110
Women without events
Low-risk 1359 118 1477
High-risk 45 56 101
Total 1404 174 1578
GA = gestational age.
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intensive care settings and very preterm infants [26]. Similarly, the
existing neonatal risk scores, such as the CRIB II score, are designed
for use in an advanced neonatal intensive care settings and rely on
data available at birth. This is not comparable in scope or proposed
environment to our model, which is designed for use in a low-
resourced community setting prior to delivery to identify those
fetuses at risk of perinatal death and for whom facility-based care
should be a priority.
The model developed in this study improves our ability to cor-
rectly identify women whose fetuses are at risk of perinatal death
beyond that of gestational age alone or the miniPIERS maternal
model. Addition of this perinatal model to the miniPIERS maternal
risk model as part of the PIERS on the Move mHealth application
[16] would result in an improvement in community-level triage
by identifying approximately 38% more women at increased risk
of perinatal loss as a result of a hypertensive disorder of pregnancy.
This would bring us closer to the ultimate goal of supporting scale-
up of community level antenatal care, including effective diagnosis
and triage of the hypertensive disorders of pregnancy, and ulti-
mately, to reduce maternal and perinatal deaths.
The data for this study were taken from the miniPIERS cohort,
designed for maternal outcome prediction, and this may have lim-
ited the final predictive performance of a perinatal risk model. The
miniPIERS cohort may be missing important potential risk factors
for stillbirth and neonatal death but no such omissions were iden-
tified based on published literature. This was a secondary analysis
of an existing cohort, so we were unable to gather additional data
in order to test a greater number of candidate predictors. A second
limitation of the study was use of a composite perinatal mortality
outcome. It could be argued that stillbirth and neonatal death will
have distinct risk factors and should be modeled separately, given
that they often have distinct causes. For example, late neonatal
deaths are often related to postnatal infection and undernutrition.
It is also important to mention that the study cohort did not
include complete follow-up to 28 days postpartum for most neo-
nates and had only limited follow-up to 7 days postpartum (7%
completeness). This lack of follow-up means late neonatal deaths
were not recorded and the model is skewed towards prediction
of events proximate to birth. Combining stillbirth and immediate
neonatal death does reflect known limitations in our ability to dif-
ferentiate these two events during data collection, as well as the
routine practice of combining these events in pre-established epi-
demiologic surveillance [27]. A final limitation of this study is the
use of gestational <34 weeks as the ‘‘gold-standard” comparator for
predictive performance of the model. This variable was chosen as it
reflects common practice in the study settings of basing assess-
ment of risk of perinatal loss on gestational age alone. There is
no other established gold-standard prognostic test for this purpose.
Among the strengths of our study is that it is based on a large
cohort of well-characterized women from five LMICs, making
results applicable across multiple under-resourced settings. Sec-
ond, by focusing on women admitted at or after 32 weeks gesta-
tion, we have assessed risk factors for perinatal death beyond
gestational age alone and removed some of the effect of prematu-
rity on the occurrence of our primary outcome. In addition, by
focusing on only those predictor variables that add significantly
to the performance of the final model we have been able to develop
a simple and useful model given the data available on assessment
in a community setting, making its implementation by community
health workers easier.
Any intervention applied in an under-resourced setting should
demonstrate added value above what already exists, while consid-
ering resource and health system implications. In this case we
would increase rates of urgent referral from the community by
approximately 9.0%, above what would have been indicated by
the maternal model alone, in order to identify an additional 30%
of high-risk women. Put differently, for every 1000 hypertensive
pregnant women identified, an additional 90 would be urgently
referred to facility to avoid not referring 21 women who would suf-
fer certain perinatal death in the community. We believe this to be
a reasonable trade-off, even though all of those perinatal deaths
would not necessarily be avoidable, due to factors such as very pre-
term gestational age.
In conclusion, this model shows great promise as a tool to iden-
tify those hypertensive pregnant women at greatest risk of perina-
tal death. The model requires further validation in a new cohort,
but once this has been accomplished, the model could be incorpo-
rated into the PIERS on the Move tool and evaluated in an imple-
mentation study that would have the potential to reduce
maternal and perinatal mortality simultaneously.
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